K-BIO Institute for Cell-Biotechnology and Immunology GmbH,
Leader in research and development(R&D) of autologous cancer immunotherapy, autologous cancer vaccine AHICE(e.g. Pancreas -Ca., Colon-Ca., none and small Cell Lung Ca. with brain metastases, Mama-Ca., etc.), as also against auto-immune diseases(e.g. MS, rheumatoide Arthritis, Morbus Waldenströmm Morbus Crohn etc.), and for prevention as well.
QUESTION: What is the autologous Cancer Vaccine AHICE, and what are its unique features and advantages?
Autologous cancer vaccine AHICE is
the in vitro synthesised totality of the complex chain of immune-response active substances in autologous plasma
of the patient in question(= greek, autologos), from which the prime material is derived, for the preparation of the cancer vaccine.
In this complex totality of immune response active substances/reagents are included physiologically numerous cytokines, chemokines, colony-stimulating-factors(CSF), and specific antibodies against the recognised epitopes of cancer-cells, including also the signal-information of cancer-cell’s membrane altered shape (⇒matrix information) pathologically.
Autologous cancer vaccine AHICE is
won out of patients own blood individually, and is targeted against recognised cancer-cells selectively.
AHICE is individual, personalised cancer immunotherapy choice per excellence.
Autologous blood (⇒ Greek = from own blood itself ) immunological treatment against cancer, named AHICE, can also defined as a special kind of "hemodialysis" in vitro (⇒ outside of patient´s body), due to eliminate, or de-masking / cleaving biochemically* the cancer-cell-membrane surface receptor-molecules.
These "receptor-, or outer-cellmembrane-molecules” are altered pathologically, as a follow up of chemical or/and viral or/and physics(e.g. radiation etc.) influences of environment on the cell-DNA, and are exprimed from them after spontaneous contact with healthy body cells.
These exprimed “receptor-molecules” are similar but not identical biochemically to those on the membrane surface of contacted healthy body cells.
QUESTION: Why is this de-masking* of the isolated cancer cells necessary?
Because, only in vitro (⇒ outside of body) it is possible to cleave, eliminate the altered membrane receptor molecules on cancer cells, with which they imitate healthy body cells!
This intelligent ability of self-protection of cancer cell-DNA against the attack of body´s immune system is called "escape mechanisms" of DNA or "cell-mimicry"** - e.g. expression of CD44v*, which is similar to adhesion receptor CD44, which charakterizes T-Lymphocytes!
With CD44v ⇒ variant, cancer cells are able to imitate T-Lymphocytes, which is a super intelligent self-protection mechanism of cancer cell DNA!
An other escape mechanism is the suppression of interaction of PD-L1 to PD-1 of T-lymphocytes.
There exist further more escape mechanisms, which are well searched scientifically.
Because of this unique intelligence** of cancer cell DNA, these** escape mechanisms to imitate healthy body cells, are the main cause, why cancer manifests itself subliminally, parallel to the existence of a physiological immune system.
Only after AHICE´s in vitro"de-masking or uncovering of the disguise"*, the altered shape of cancer cells is being visible, after which body's own immune system becoming able to recognise them (⇒ the naked cancer cells) as differentiated body cells pathologically.
In the following the immune system reacts spontaneously via the targeted immune response, followed by elimination of recognized cancer cells apoptotically
- see also the life visualisation of spontaneous immune response, click here → AHIZE Visualisierung (⇒ visible making).
Clinical Studies have shown that this apoptotic process takes place not only on the side of solid tumours, but also at all micro metastases everywhere in the whole organism! This is meaningful, because of elimination the possibility of the appearance metastases in the future - this is the unique advantage of autologous cancer immunotherapy AHICE, besides the absence of side effects.
QUESTION: IS SUCCESSFUL CANCER-THERAPY POSSIBLE?
In 1995 the German-Carcinoma-Research-Centre(DKFZ), Heidelberg, has examined statistically the therapeutic results earned by application of conservative tumourtherapy on various kinds of tumours. In conclusion of that, conservative cancertherapy (that is the combined application of surgical tumour-removal + radiation + chemotherapy) decreases the surviving chance of cancerpatients down to a level of 5% (Origin: FOCUS, 19, 1995)¹. This alarming bad therapy-result is equal with the global refusal of conservative cancertherapy, which is only trying to fight the symptomatics of carcinoma, applicating celltoxic substances (that have poor cell selectivity-ability), but not against the casualty of establishing carcinoma in patient´s organism. By the force of applicated conservative tumourtherapy( i. e. cytostatics, or radiation, or both) especially patient´s immune-system will be strongly depressed. In conjunction, bone marrow as stemmcell-reservoir, liver and kidney were damaged on the celltoxic influence of applicated chemotherapy-schemata - radiation- and chemotherapy causes various toxic secondary effects, upon general recognition. In addition, therapy-costs are very high in relation to doubtful therapy-results of conservative cancertherapy.
QUESTION: What other cancer-therapies, probably more efficient, without side effects, selective active against cancer-cells can fight successful carcinomata over long terms?
Oncology-specialized scientists, all over the world are of one mind, that a successful fight against carcinoma basically will be possible only upon generation of appropriate immunologic cancer-therapyforms*. That means
the specific activation of patient´s immune-system against the altered cancer cells,
including newest biological, immunological, molecular-biological methods and bio-engineering***.
*** Prof. Harald zur Hausen, DKFZ, see webpage www.dkfz.de, lecture on 29.October 1999, pages 2. and 6., suggests that the immunological cancer-therapy will be the only one therapeutical method, which will bring now and in the future the most outstanding specific therapeutic effects.
Quotation:"....The National Cancer Institute of the United States of America(NCI) calls in the early 90ies five main-areas, out of that future pioneering developments for the cancer-research and -therapy have to be expected. These are:
- the immune-biology and the immunotherapy - it meant to be like our autologous cancer immunotherapy AHICE -
- the cell-biology,
- the Genes-Science and the Genetics,
- the molecular Epidemiology and
- the Bioinformatics.
K-BIO Institute agrees with that conviction.
Even convinced of the cancer immunotherapy as well, are many scientits around the world, e. g.:
Cassian Yee and colleagues of Fred Hutchinson cancer research centre in Seatle, USA, are at once convinced with that. They report a therapeutic-effect of 80% with their immunological cancer therapy: Welt am Sonntag, 46 (2002), medicine, p. 31.
In this regard published the scientific journal "Science" , quotation: ".. 2013 .. the greatest and most important discovery..the immunotherapy of cancer.."
this means the official scientific recognition of cancer immunotherapy!
On that thematics were carried out projects scientifically all over the world over the last three decades of years, to find out suitable cancer-therapy concepts on immunological basis, most of them acing the "dogma" of pharmacy - it meant, to find an agent suitable for fighting cancer, and multiplicate it industrially as a multi-purpose "medicine". On the other hand, this is not immunotherapy, but "chemotherapy" per definitionem!
However, till now, there have been recorded only a few therapeutic successes and only for a few kinds of carcinomata.
The reason for that failure is due to applicate only one, or a few heterologous (recombinant) synthesised intermediate factors, instead of the whole complex chain of autologous synthesised (⇒ from immune system itself produced) immune-response-working-substances of activation- and auto-regulation chain of patient´s own immune system, including the "information" of altered pathologically matrix of recognized cancer cells!
On this key-relationship, Dr. H. Anthopoulos has developed the target tumourcell specific, active cancer immunotherapy, autologous vaccine AHICE, for active immunotherapy of cancer, cancer-aftercare, for auto-immune diseases and for prevention as well, after a long term of immunological / biochemical scientific research and developmental work.
Cancer immunotherapy AHICE is involving
the complex totality of immune-response working substances-chain in autologous blood-plasma, as this is resulted from the specific immune-response against recognised cancer cells (international patent), including the specific information of altered shape of recognised cancer cells as well.
Therefore, autologous immunotherapy AHICE is unique specific only against cancer cells and is "personalized cancer immunotherapy per excellence".
AHICE´s in vivo effectiveness is being proved over clinical trials with co-operative medicinal institutions until now on various carcinomata (⇒ Remissions, mostly, when patiens fullfil the prerequisites for AHICE Vaccine-Processing).
Also remarkable therapy-results have been achieved on treatment of auto-immune-diseases, such as Hashimoto Thyreoiditis, Rheumatoid Arthritis, Morbus Waldenstroem, MS, Morbus Crohn, Colitis Ulcerosa, for example.
Autologous cancer vaccine AHICE is performed and applied clinical individually, because of autology, by patient´s responsible doctor exclusively - according to §13, 2b, German Drug Law AMG.
Autologous cancer vaccine AHICE belongs to new advanced therapies in accordance with ATMP regulation 1394/2007/EG for new somatic cell and gene therapies, at which the therapeutic effect in vivo is led with a specific immune response.
In accordance with no. 6 of this regulation is AHICE freed from these regulations if it is produced and applied by the doctor in a hospital or clinic for his selected patients!
K BIO institute is active in applied immunological/ biochemical/physical-chemistry/molecular-biology and radiation-biology research and development (R & D), and on the field of researching further "escape mechanisms" of cancer-cells, as also in educating and organising seminars in immunology, cell-biology, aseptic working procedures according to GMP guideline/EC and German AMWHV.
Medicinal institutions/hospitals/clinics/physicians(MD) with the required deeper going immunological knowledges, as well as with the GMP guideline/EC and German AMWHV demanded equipment (clean-room facility / immunology and experience in cell-biology / aseptic lab-working), are welcome to acquire licenses to process the autologous cancer vaccine, cancer immunotherapy AHICE for their selected patients in autonomy, and get the allowance to use AHICE clinically - for grave licence inquiries, please, you are welcome to consult the CEO of K-BIO institute → contact .
Because of that autologous Vaccine AHICE is to be established on highest level both ethically and economically as well, we are quite particularly pleased about turnings to support of our scientific work, as also about scientific co operations → contact
We like to be available
K-BIO institute for cell-biotechnology and immunology
Tel.+49-8142-4106200,fax:+49-8142-4106202, e-mail: Info[at]K-BIO-Institut.de
Cancer Immunotherapy, Autologous Vaccine AHICE, colon-, mamma-, peritoneal-, pancreas-, small-cell-lung-ca., treatment results
* Literature, scientific publication
Authors: H. Anthopoulos* & K.-H. Regele**
*K-BIO Institute for Cellbiotechnology and Immunology GmbH,
**Medical Ordination for Immunotherapy at K-BIO Institute for
Cellbiotechnology and Immunology GmbH, Groebenzell, Germany(-2012)
Autologous human cancer vaccine, autologous cancer immunotherapy AHICE is distinguished by its unique selectivity and specificity against recognized cancer-cells not only at the site of solid tumours but everywhere in the whole organism.
The peculiarity of AHICE is the demasking of cancer-cells biochemically prior to cancer vaccine preparation.
Following that the autologous immune system is becoming able to detect circulating cancer cells selectively and eliminates these recognized cancer cells spontaneously.
AHICE is being either sub cutan or i.v. administered.
Before and after AHICE were examined:
A differential blood count, an immune-phenotyping of lymphocytes, the related tumor markers, TNF-a-, IFN-γ blood-plasma concentrations.
At the end of AHICE treatment the tumor situation was examined (MRI, CT or/and PET scan).
Results for example:
colon-ca. overcomes 13 years, is still living without neoplasies ⇒ REMISSION (MRI).
pancreas ca. after surgery have had a rest life prolongation of over 9 years, instead approximately 6 months with or without conservative therapy!
peritoneal multifocal cancer in June 2004 have had REMISSION (CT) after the 1st AHICE cycle, is still living without neoplasies >15 years (MRI).
breast ca. overcomes the 5 years living without neoplasies at best quality of life.
A small-cell lung-ca., male patient (two brain metastases, condition after radiation treatment, surgery of the lung tumours).
After AHICE: No more neoplasies were noticed in the lung, liver and one brain-meta was melted down (over 2 years AHICE treatment-observation). The second brain-meta showed only a small active peripheral region, agent incorporating area (PET scan). Excision of the tumor was carried out. Immunohistochemically showed multiple necrotic cells and increased CD56+ on cells (⇒ Natural Killer Cells NKC´s), as this is the proof of the in vivo brain effectiveness of AHICE!
In conclusion we can refer that after a previous demasking of cancer cells, and the following spontaneous immune response, resulting in the production of complex totality of all immune response working substances, including the antigen information of altered cells pathologically, the so activated autologous immune system is the significant point of reference for successful cancer therapy
Care must be taken to keep immune system on physiological level during autologous Immunotherapy by avoiding of any other medication, which is well known suppriming it, such as cortisole or its analoga, dexamethasone, analgesics, antiphlegmonics, antiepileptics etc..
This Abstract was published in:
Abstracts of the Annual Congress of the British Society for Immunology, 5–8 December 2011, J. Immunology, P. 830
Liverpool, UK, Editor Daniel Altmann, J. Immunology, Volume 135, Suppl. 1, December 2011, The Journal of cells, molecules, systems and technologies.
1. "Spezialeinheit auf Mordmision", M. Zöller et Al. "der Spiegel", 35, 230, 1992
2. "Participation in normal immune responses of a metastasis-inducing splice variant of cd 44", M. Zöller et al., "Science", Vol. 257, 682, 31. July, 1992.
3. "PD-L1 Expression Correlates with Tumour-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer", Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL, Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.
Furthermore scientific informations:
K-BIO Clinical Biochemical Institute for Cellbiotechnology and Immunology GmbH
previous → choose your language next → we about us
next → products
next → Immunotherapy AHICE
next → Thyreoidea Gland Cancer
next → Auto Immune Diseases
next → Morbus Waldenstroem
next → Peritoneal Cancer
next → Prostate Gland Cancer
next → CEO,Researcher,Ερευνητης
next → Investors,
next → contact,